Grünenthal to receive ~$525M incl. $75M up front & is eligible to receive $70M in milestones before regulatory approval along with additional sales-based fees
Shionogi to get exclusive commercialization rights for Resiniferatoxin (RTX) in Japan. Resiniferatoxin (TRPV1 agonist) is currently being studied in the P-III trial for pain associated with osteoarthritis of the knee across sites in the EU, US, Latin America, South Africa & Japan
If the P-III trial results are positive, Grünenthal plans to advance the RTX for osteoarthritis-related pain in other joints. If RTX is approved, it will be a non-opioid therapy option that provides long-lasting pain relief along with functional improvement of the affected knee joint & will be well tolerated
Ref: PR Newswire | Image: Shionogi
